CorAssist Cardiovascular - Innovative Solutions for heart failure with preserved ejection fraction (HFpEF)
Over 5.7 million people in the US
and 20 million people worldwide
suffer from heart failure.
CorAssist Cardiovascular - Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

Our Solution - Innovative Devices for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

CorAssist is developing a pipeline of elastic, self-expanding devices that are attached to the left ventricle, in minimally invasive procedures. The devices operate by transferring energy harnessed during systole (contraction) to the left ventricle during diastole (relaxation) to improve diastolic performance. CorAssist’s devices deal with the core problems of HFpEF – the stiffening of the myocardial tissue and impaired relaxation – by directly enhancing the elastic characteristics of the left ventricular wall.


The CORolla® is an elastic device implanted inside the left ventricle in a minimally invasive procedure through Trans Apical Approach (TAA) or Percutaneous Approach (PA) in an off-pump procedure. The device applies direct internal expansion forces distributed on the left ventricle wall and the septum to improve diastolic function.
In-Vivo safety evaluation was finalized demonstrating safety up to 24 months follow up.
First-in-man stand-alone clinical study was initiated and currently recruiting patients.
Click here to see the CORolla® demo.